Highlights from the latest articles in CYP2D6 activity and breast cancer outcomes during treatment with tamoxifen

被引：0

作者：

Dorado, Pedro ^{[1
]}

Penas-Lledo, Eva ^{[1
]}

LLerena, Adrian ^{[1
,2
]}

机构：

[1] Extremadura Univ Hosp & Med Sch, Clin Res Ctr, CICAB, Badajoz 06080, Spain

[2] Inst Salud Carlos III, CIBERSAM, Madrid, Spain

来源：

PHARMACOGENOMICS | 2013年 / 14卷 / 06期

关键词：

POSTMENOPAUSAL WOMEN; ADJUVANT TAMOXIFEN; GENOTYPE; PHARMACOGENETICS; MARKER; TRIAL;

D O I：

10.2217/pgs.13.42

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：603 / 604

页数：2

共 13 条

[1]

COEZY E, 1982, CANCER RES, V42, P317

[2] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6 [J].

Desta, Z ;

Ward, BA ;

Soukhova, NV ;

Flockhart, DA .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 310 (03) :1062-1075

[3] Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use [J].

Dorado, P ;

Cáceres, MC ;

Pozo-Guisado, E ;

Wong, ML ;

Licinio, J ;

Llerena, A .

BIOTECHNIQUES, 2005, 39 (04) :571-574

[4] CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8 [J].

Goetz, Matthew P. ;

Suman, Vera J. ;

Hoskin, Tanya L. ;

Gnant, Michael ;

Filipits, Martin ;

Safgren, Stephanie L. ;

Kuffel, Mary ;

Jakesz, Raimund ;

Rudas, Margaretha ;

Greil, Richard ;

Dietze, Otto ;

Lang, Alois ;

Offner, Felix ;

Reynolds, Carol A. ;

Weinshilboum, Richard M. ;

Ames, Matthew M. ;

Ingle, James N. .

CLINICAL CANCER RESEARCH, 2013, 19 (02) :500-507

[5] Pharmacogenetics of Endocrine Therapy for Breast Cancer [J].

Higgins, Michaela J. ;

Stearns, Vered .

ANNUAL REVIEW OF MEDICINE, VOL 62, 2011, 2011, 62 :281-293

[6] CYP2D6 Genotype as a Marker for Benefit of Adjuvant Tamoxifen in Postmenopausal Women: Lessons Learned [J].

Kelly, Catherine M. ;

Pritchard, Kathleen I. .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (06) :427-428

[7] Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity [J].

LLerena, Adrian ;

Dorado, Pedro ;

Penas-Lledo, Eva M. .

PHARMACOGENOMICS, 2009, 10 (01) :17-28

[8]

Newman WG, 2012, PHARMACOGENOMICS, V13, P629, DOI [10.2217/PGS.12.37, 10.2217/pgs.12.37]

[9] The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels [J].

Opdam, F. L. ;

Dezentje, V. O. ;

den Hartigh, J. ;

Modak, A. S. ;

Vree, R. ;

Batman, E. ;

Smorenburg, C. H. ;

Nortier, J. W. R. ;

Gelderblom, H. ;

Guchelaar, H. -J. .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (03) :593-601

[10] CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients [J].

Rae, James M. ;

Drury, Suzy ;

Hayes, Daniel F. ;

Stearns, Vered ;

Thibert, Jacklyn N. ;

Haynes, Ben P. ;

Salter, Janine ;

Sestak, Ivana ;

Cuzick, Jack ;

Dowsett, Mitch .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (06) :452-460

← 1 2 →